New approach to HIV prevention for transgender women shows promise
NCT ID NCT04742491
Summary
This study tested whether combining HIV prevention medication (PrEP) with gender-affirming hormone therapy and peer health navigation would help transgender women start and stay on PrEP. 304 transgender women across the Americas were randomly assigned to receive this combined care immediately or after a 6-month wait. The research measured how many women started PrEP, how consistently they took it, and whether they found the combined services helpful.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV PREVENTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bridge HIV CRS
San Francisco, California, 94102, United States
-
Harlem Prevention Center CRS
New York, New York, 10027, United States
-
Houston AIDS Research Team CRS
Houston, Texas, 77030, United States
-
Instituto de Pesquisa Clinicaq Evandro Chagas CRS
Manguinhos, Rio de Janeiro, 221045-900, Brazil
-
Penn Prevention CRS
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.